Welcome to the 4th Inflammasome Therapeutics Summit
The 4th Inflammasome Therapeutics Summit returns to Boston, uniting industry pioneers during this exciting new era in inflammasome therapeutic research.
With NLRP3’s first clinical readouts expected later this year, progress in other inflammasomes accelerating like never before, this is the time to unite with your expert peers to address mechanistic understanding, disease selection and application, preclinical model progress, the push into the clinic to propel the next frontier of inflammasome therapeutics from pipeline to clinical & commercial reality
Gathering industry heavyweights including NodThera, Novartis, Roche, ZyVersa Therapeutics, and more, this is your chance to join forces with fellow inflammasome pioneers and be involved in interactive discussions on:
Deciphering the intricate mechanisms underlying dysregulated inflammasome signaling within the wider context of the immune system
Overcoming limitations of preclinical models, identifying clinically meaningful biomarkers of inflammasome inhibition, and identifying good clinical endpoints
Taming inflammation and achieving optimized safety profiles using the next frontier for inflammasome-targeted drugs including those targeting NLRP3 and novel targets
Identifying emerging immune signatures to identify patient responders
Delving into specific disease groups to demonstrate where inflammasome therapeutics will be most impactful
Your 2022 Speaker Faculty Included:
Kate Fitzgerald
Professor & Vice Chair, Department of Medicine Division of Innate Immunity
University of Massachusetts Chan Medical School
2022 Attendees Included:
Proud to Partner with:
